Assessment of primary haemostasis with a new recombinant von Willebrand factor in patients with von Willebrand disease

Haemophilia. 2020 Mar;26(2):e44-e48. doi: 10.1111/hae.13916. Epub 2019 Dec 22.

Authors

Marc Trossaërt¹, Claire Flaujac², Emmanuelle Jeanpierre³, Nicolas Drillaud¹, Marianne Sigaud¹, Marc Fouassier¹, Catherine Ternisien¹, Emmanuelle de Raucourt²

Affiliations

¹ Department of Haemostasis, University Hospital of Nantes, Nantes, France.
² Department of Haemostasis, Hospital of Versailles, Versailles, France.
³ Department of Haemostasis, University Hospital of Lille, Lille, France.

PMID: 31865618
DOI: 10.1111/hae.13916

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Angiodysplasia / complications
Angiodysplasia / physiopathology
Deamino Arginine Vasopressin / therapeutic use
Factor VIII / metabolism
Female
Hemostasis / physiology*
Hemostatics / therapeutic use
Humans
Infusions, Intravenous / methods
Middle Aged
Platelet Function Tests / methods
Treatment Outcome
von Willebrand Diseases / complications
von Willebrand Diseases / drug therapy*
von Willebrand Diseases / genetics
von Willebrand Diseases / physiopathology
von Willebrand Factor / administration & dosage
von Willebrand Factor / metabolism
von Willebrand Factor / therapeutic use*

Substances

Hemostatics
von Willebrand Factor
Factor VIII
Deamino Arginine Vasopressin